Zacks Investment Research upgraded shares of CHINA BIOLOGIC (CBPO) from NEUTRAL to OUTPERFORM on January 26, 2015, with a target price of $82.00.
China Biologic Products, Inc., through its indirect majority-owned subsidiary, is principally engaged in the research, development, production, manufacturing and sale of plasma-based biopharmaceutical products to hospitals and other health care facilities in China. Its subsidiary, Shandong Taibang Biological Products Company Ltd., operates from its manufacturing facility located in Taian City, Shandong Province. The Company's principal products include its approved human albumin and immunoglobulin products. These human albumin products are mainly used to increase blood volume and its immunoglobulin products are used for the treatment and prevention of diseases.
To get a free copy of the research report on CHINA BIOLOGIC (CBPO),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment